Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15848963 | 0.93 | HASPIN (0.61) | HASPINDYRK1AHTR2AHTR2CSMPD1 | |
| SCHEMBL600292 | 0.83 | CNR2 (0.55) | HASPINDYRK1AHTR2AHTR2CKMT2A | |
| SCHEMBL30663727 | 0.83 | HASPIN (0.94) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL16102805 | 0.83 | HASPIN (0.94) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL31609253 | 0.79 | HASPIN (0.58) | HASPINDYRK1A | |
| SCHEMBL6859526 | 0.79 | DYRK1A (0.60) | HASPINDYRK1A | |
| Hydrochloric Acid SCHEMBL8757541 | 0.79 | HASPIN (0.69) | HASPINDYRK1ACYP2D6 | |
| SCHEMBL15227840 | 0.79 | HASPIN (1.00) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17297930 | 0.79 | CSF1R (0.54) | HASPINDYRK1AHTR2AHTR2CSMPD1 | |
| SCHEMBL18262982 | 0.79 | KDM4E (0.54) | HASPINSMPD1HTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| EP-2356093-A1 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (RU) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | HASPIN 1706/4885DYRK1A 3482/4885HTR2A 4156/4885 |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | HASPIN 1706/4885DYRK1A 3482/4885HTR2A 4156/4885 |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | MALT1, PAICS, BCL9 | HASPIN 1706/4885DYRK1A 3482/4885HTR2A 4156/4885 |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | MALT1, PAICS, TPMT | HASPIN 1780/4885DYRK1A 3528/4885HTR2A 4183/4885 |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | HASPIN 1706/4885DYRK1A 3482/4885HTR2A 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.